Additionally, Sikiric is listed online as the CEO of a company called Diagen, which says it owns a patent for a special stable version of BPC-157
We often see researchers exploring the Fat Loss & Metabolic Health Bundle when these compounds are under consideration
The short version: BPC-157 has genuinely interesting biology and promising preclinical data
This is your chance to win amazing discounts
TATA boxes in gene transcription and poly (A) tails in mRNA stability: new perspective on the effects of berberine
They further modified DMB and developed inhibitors targeting CutC and CutD, the major microbial TMA-generating enzyme pair, and when administered as a single oral dose, significantly decreased plasma TMAO concentrations for up to 3 days and rescued the diet-induced enhancements in platelet reactivity and thrombosis in animal models, without increasing bleeding risk or toxicity (Roberts et al., 2018)